# US 2005/0233445 A1 · Biomimetic urothelium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233445 A1
- Document ID: US20050233445A1
- Status: Published application
- Kind: A1
- Application number: 10/522,371
- Filed: 2003-07-28
- Published: 2005-10-20
- Earliest claimed: 2002-07-26
- Assignees: The University of York
- Inventors: William Cross; Jennifer Southgate
- Web page: https://patentgrep.com/patent/US20050233445A1

## CPC

- C12N 5/0684: {Cells of the urinary tract or kidneys}
- C12N 2500/84: from mammals
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2502/25: Urinary tract cells, renal cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Urothelium is the specialised endothelium that lines much of the mammalian urinary tract. This invention relates to the field of in vitro urothelial culture. Previous methods produce tissue lacking much of the functionality of native urothelium. In this invention, stratified, differentiated mammalian urothelium is produced by passaging urothelial cells through a nutrient medium containing serum, and redispersed, before going on in a like medium to form said urothelium.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method of production of stratified, differentiated mammalian urothelium in which urothelial cells, isolated from the mammalian body, are passaged through a nutrient medium containing the components of serum and redispersed before going on in a like medium to form said urothelium.

### Claim 14 (depends on 13)

The method of claim 13 wherein the mammalian urothelium is human urothelium.

### Claim 15 (depends on 13)

The method of claim 13 in which the serum is bovine serum.

### Claim 16 (depends on 15)

The method of claim 15 in which the serum is adult bovine serum.

### Claim 17 (depends on 13)

The method of claim 13 in which the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 1% and about 30% related to the concentration of said components in whole serum.

### Claim 18 (depends on 13)

The method of claim 13 in which the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 3% and about 10% related to the concentration of said components in whole serum.

### Claim 19 (depends on 13)

The method of claim 13 wherein the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 4% and about 6% related to the concentration of said components in whole serum.

### Claim 20 (depends on 13)

The method of claim 13 wherein the nutrient medium is, or is a derivative of, MCDB-153 medium.

### Claim 21 (depends on 13)

The method of claim 13 wherein the nutrient medium is KSFM (Keratinocyte Serum Free Medium).

### Claim 22 (depends on 13)

The method of claim 13 wherein the nutrient medium is supplemented by one or more of Epidermal Growth Factor (EGF); Bovine Pituitary Extract (BPE); Cholera Toxin (CT).

### Claim 23 (depends on 13)

Urothelium produced by the method of claim 13.
